Skip to main content
Top
Published in: Hepatology International 2/2024

31-03-2023 | Original Article

Characteristics of microbiome-derived metabolomics according to the progression of alcoholic liver disease

Authors: Raja Ganesan, Haripriya Gupta, Jin-Ju Jeong, Satya Priya Sharma, Sung-Min Won, Ki-Kwang Oh, Sang Jun Yoon, Sang Hak Han, Young Joo Yang, Gwang Ho Baik, Chang Seok Bang, Dong Joon Kim, Ki Tae Suk

Published in: Hepatology International | Issue 2/2024

Login to get access

Abstract

Background and aim

The prevalence and severity of alcoholic liver disease (ALD) are increasing. The incidence of alcohol-related cirrhosis has risen up to 2.5%. This study aimed to identify novel metabolite mechanisms involved in the development of ALD in patients. The use of gut microbiome-derived metabolites is increasing in targeted therapies. Identifying metabolic compounds is challenging due to the complex patterns that have long-term effects on ALD. We investigated the specific metabolite signatures in ALD patients.

Methods

This study included 247 patients (heathy control, HC: n = 62, alcoholic fatty liver, AFL; n = 25, alcoholic hepatitis, AH; n = 80, and alcoholic cirrhosis, AC, n = 80) identified, and stool samples were collected. 16S rRNA sequencing and metabolomics were performed with MiSeq sequencer and liquid chromatography coupled to time-of-flight–mass spectrometry (LC–TOF–MS), respectively. The untargeted metabolites in AFL, AH, and AC samples were evaluated by multivariate statistical analysis and metabolic pathotypic expression. Metabolic network classifiers were used to predict the pathway expression of the AFL, AH, and AC stages.

Results

The relative abundance of Proteobacteria was increased and the abundance of Bacteroides was decreased in ALD samples (p = 0.001) compared with that in HC samples. Fusobacteria levels were higher in AH samples (p = 0.0001) than in HC samples. Untargeted metabolomics was applied to quantitatively screen 103 metabolites from each stool sample. Indole-3-propionic acid levels are significantly lower in AH and AC (vs. HC, p = 0.001). Indole-3-lactic acid (ILA: p = 0.04) levels were increased in AC samples. AC group showed an increase in indole-3-lactic acid (vs. HC, p = 0.040) level. Compared with that in HC samples, the levels of short-chain fatty acids (SCFAs: acetic acid, butyric acid, propionic acid, iso-butyric acid, and iso-valeric acid) and bile acids (lithocholic acids) were significantly decreased in AC. The pathways of linoleic acid metabolism, indole compounds, histidine metabolism, fatty acid degradation, and glutamate metabolism were closely associated with ALD metabolism.

Conclusions

This study identified that microbial metabolic dysbiosis is associated with ALD-related metabolic dysfunction. The SCFAs, bile acids, and indole compounds were depleted during ALD progression.

Clinical trial

Clinicaltrials.gov, number NCT04339725.
Appendix
Available only for authorised users
Literature
1.
go back to reference Nath B, Szabo G. Alcohol-induced modulation of signaling pathways in liver parenchymal and nonparenchymal cells: implications for immunity. Semin Liver Dis. 2009;29(2):166–177PubMedCrossRef Nath B, Szabo G. Alcohol-induced modulation of signaling pathways in liver parenchymal and nonparenchymal cells: implications for immunity. Semin Liver Dis. 2009;29(2):166–177PubMedCrossRef
3.
go back to reference Ganesan R, Yoon SJ, Suk KT. Microbiome and metabolomics in liver cancer: scientific technology. Int J Mol Sci. 2023;24(1):537CrossRef Ganesan R, Yoon SJ, Suk KT. Microbiome and metabolomics in liver cancer: scientific technology. Int J Mol Sci. 2023;24(1):537CrossRef
4.
go back to reference Bajaj JS. Alcohol, liver disease and the gut microbiota. Nat Rev Gastroenterol Hepatol. 2019;16(4):235–246PubMedCrossRef Bajaj JS. Alcohol, liver disease and the gut microbiota. Nat Rev Gastroenterol Hepatol. 2019;16(4):235–246PubMedCrossRef
5.
go back to reference Addolorato G, et al. Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease. Liver Int. 2020;40(4):878–888PubMedCrossRef Addolorato G, et al. Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease. Liver Int. 2020;40(4):878–888PubMedCrossRef
6.
go back to reference Parlesak A, et al. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol. 2000;32(5):742–747PubMedCrossRef Parlesak A, et al. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol. 2000;32(5):742–747PubMedCrossRef
7.
8.
go back to reference Arvaniti V, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010;139(4):1246–1256 (1256 e1–5)PubMedCrossRef Arvaniti V, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010;139(4):1246–1256 (1256 e1–5)PubMedCrossRef
9.
10.
go back to reference Han SH, et al. Effects of probiotics (cultured Lactobacillus subtilis/Streptococcus faecium) in the treatment of alcoholic hepatitis: randomized-controlled multicenter study. Eur J Gastroenterol Hepatol. 2015;27(11):1300–1306PubMedCrossRef Han SH, et al. Effects of probiotics (cultured Lactobacillus subtilis/Streptococcus faecium) in the treatment of alcoholic hepatitis: randomized-controlled multicenter study. Eur J Gastroenterol Hepatol. 2015;27(11):1300–1306PubMedCrossRef
11.
go back to reference Coen M, et al. NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chem Res Toxicol. 2008;21(1):9–27PubMedCrossRef Coen M, et al. NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chem Res Toxicol. 2008;21(1):9–27PubMedCrossRef
13.
go back to reference Raja G, et al. Recent advances of microbiome-associated metabolomics profiling in liver disease: principles, mechanisms, and applications. Int J Mol Sci. 2021;22(3):1160PubMedPubMedCentralCrossRef Raja G, et al. Recent advances of microbiome-associated metabolomics profiling in liver disease: principles, mechanisms, and applications. Int J Mol Sci. 2021;22(3):1160PubMedPubMedCentralCrossRef
15.
go back to reference Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell. 2008;134(5):714–717PubMedCrossRef Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell. 2008;134(5):714–717PubMedCrossRef
19.
go back to reference Noecker C, et al. Defining and evaluating microbial contributions to metabolite variation in microbiome-metabolome association studies. mSystems. 2019;4(6):e00579PubMedPubMedCentralCrossRef Noecker C, et al. Defining and evaluating microbial contributions to metabolite variation in microbiome-metabolome association studies. mSystems. 2019;4(6):e00579PubMedPubMedCentralCrossRef
20.
go back to reference Ferrarini A, et al. Metabolomic analysis of liver tissues for characterization of hepatocellular carcinoma. J Proteome Res. 2019;18(8):3067–3076PubMedCrossRef Ferrarini A, et al. Metabolomic analysis of liver tissues for characterization of hepatocellular carcinoma. J Proteome Res. 2019;18(8):3067–3076PubMedCrossRef
21.
go back to reference Pan HY, et al. LC/MS-based global metabolomic identification of serum biomarkers differentiating hepatocellular carcinoma from chronic hepatitis b and liver cirrhosis. ACS Omega. 2021;6(2):1160–1170PubMedPubMedCentralCrossRef Pan HY, et al. LC/MS-based global metabolomic identification of serum biomarkers differentiating hepatocellular carcinoma from chronic hepatitis b and liver cirrhosis. ACS Omega. 2021;6(2):1160–1170PubMedPubMedCentralCrossRef
22.
go back to reference Yoon SH, et al. Introducing EzBioCloud: a taxonomically united database of 16S rRNA gene sequences and whole-genome assemblies. Int J Syst Evol Microbiol. 2017;67(5):1613–1617PubMedPubMedCentralCrossRef Yoon SH, et al. Introducing EzBioCloud: a taxonomically united database of 16S rRNA gene sequences and whole-genome assemblies. Int J Syst Evol Microbiol. 2017;67(5):1613–1617PubMedPubMedCentralCrossRef
23.
go back to reference Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 2010;26(19):2460–2461PubMedCrossRef Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 2010;26(19):2460–2461PubMedCrossRef
25.
go back to reference Douglas GM, Beiko RG, Langille MGI. Predicting the functional potential of the microbiome from marker genes using PICRUSt. Methods Mol Biol. 2018;1849:169–177PubMedCrossRef Douglas GM, Beiko RG, Langille MGI. Predicting the functional potential of the microbiome from marker genes using PICRUSt. Methods Mol Biol. 2018;1849:169–177PubMedCrossRef
26.
go back to reference Han J, et al. An isotope-labeled chemical derivatization method for the quantitation of short-chain fatty acids in human feces by liquid chromatography-tandem mass spectrometry. Anal Chim Acta. 2015;854:86–94PubMedCrossRef Han J, et al. An isotope-labeled chemical derivatization method for the quantitation of short-chain fatty acids in human feces by liquid chromatography-tandem mass spectrometry. Anal Chim Acta. 2015;854:86–94PubMedCrossRef
27.
go back to reference Park SJ, et al. Exposure of ultrafine particulate matter causes glutathione redox imbalance in the hippocampus: a neurometabolic susceptibility to Alzheimer’s pathology. Sci Total Environ. 2020;718: 137267PubMedCrossRef Park SJ, et al. Exposure of ultrafine particulate matter causes glutathione redox imbalance in the hippocampus: a neurometabolic susceptibility to Alzheimer’s pathology. Sci Total Environ. 2020;718: 137267PubMedCrossRef
28.
go back to reference Lee NY, et al. Lactobacillus and Pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome. Gut Microbes. 2020;11:1–18CrossRef Lee NY, et al. Lactobacillus and Pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome. Gut Microbes. 2020;11:1–18CrossRef
29.
go back to reference Ji DY, et al. Comparative assessment of Graves’ disease and main extrathyroidal manifestation, Graves’ ophthalmopathy, by non-targeted metabolite profiling of blood and orbital tissue. Sci Rep. 2018;8(1):9262PubMedPubMedCentralCrossRef Ji DY, et al. Comparative assessment of Graves’ disease and main extrathyroidal manifestation, Graves’ ophthalmopathy, by non-targeted metabolite profiling of blood and orbital tissue. Sci Rep. 2018;8(1):9262PubMedPubMedCentralCrossRef
30.
go back to reference Polyzos AA, et al. Metabolic reprogramming in astrocytes distinguishes region-specific neuronal susceptibility in huntington mice. Cell Metab. 2019;29(6):1258-1273.e11PubMedPubMedCentralCrossRef Polyzos AA, et al. Metabolic reprogramming in astrocytes distinguishes region-specific neuronal susceptibility in huntington mice. Cell Metab. 2019;29(6):1258-1273.e11PubMedPubMedCentralCrossRef
31.
go back to reference Lee NY, et al. Lactobacillus and Pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome. Gut Microbes. 2020;11(4):882–899PubMedPubMedCentralCrossRef Lee NY, et al. Lactobacillus and Pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome. Gut Microbes. 2020;11(4):882–899PubMedPubMedCentralCrossRef
33.
go back to reference Pang Z, et al. Using MetaboAnalyst 5.0 for LC–HRMS spectra processing, multi-omics integration and covariate adjustment of global metabolomics data. Nat Protoc. 2022;17(8):1735–1761PubMedCrossRef Pang Z, et al. Using MetaboAnalyst 5.0 for LC–HRMS spectra processing, multi-omics integration and covariate adjustment of global metabolomics data. Nat Protoc. 2022;17(8):1735–1761PubMedCrossRef
34.
go back to reference Guy J, Peters MG. Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes. Gastroenterol Hepatol (N Y). 2013;9(10):633–639PubMed Guy J, Peters MG. Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes. Gastroenterol Hepatol (N Y). 2013;9(10):633–639PubMed
35.
go back to reference Zhao ZH, et al. Indole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage to attenuate steatohepatitis in rats. Exp Mol Med. 2019;51(9):1–14PubMedPubMedCentralCrossRef Zhao ZH, et al. Indole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage to attenuate steatohepatitis in rats. Exp Mol Med. 2019;51(9):1–14PubMedPubMedCentralCrossRef
36.
go back to reference Bjorndal B, et al. Associations between fatty acid oxidation, hepatic mitochondrial function, and plasma acylcarnitine levels in mice. Nutr Metab (Lond). 2018;15:10PubMedCrossRef Bjorndal B, et al. Associations between fatty acid oxidation, hepatic mitochondrial function, and plasma acylcarnitine levels in mice. Nutr Metab (Lond). 2018;15:10PubMedCrossRef
37.
go back to reference Vasavan T, et al. Heart and bile acids—clinical consequences of altered bile acid metabolism. Biochim Biophys Acta Mol Basis Dis. 2018;1864(4 Pt B):1345–1355PubMedCrossRef Vasavan T, et al. Heart and bile acids—clinical consequences of altered bile acid metabolism. Biochim Biophys Acta Mol Basis Dis. 2018;1864(4 Pt B):1345–1355PubMedCrossRef
38.
39.
go back to reference Bull-Otterson L, et al. Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment. PLoS ONE. 2013;8(1): e53028PubMedPubMedCentralCrossRef Bull-Otterson L, et al. Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment. PLoS ONE. 2013;8(1): e53028PubMedPubMedCentralCrossRef
40.
go back to reference Shin NR, Whon TW, Bae JW. Proteobacteria: microbial signature of dysbiosis in gut microbiota. Trends Biotechnol. 2015;33(9):496–503PubMedCrossRef Shin NR, Whon TW, Bae JW. Proteobacteria: microbial signature of dysbiosis in gut microbiota. Trends Biotechnol. 2015;33(9):496–503PubMedCrossRef
41.
go back to reference Warshakoon HJ, Burns MR, David SA. Structure-activity relationships of antimicrobial and lipoteichoic acid-sequestering properties in polyamine sulfonamides. Antimicrob Agents Chemother. 2009;53(1):57–62PubMedCrossRef Warshakoon HJ, Burns MR, David SA. Structure-activity relationships of antimicrobial and lipoteichoic acid-sequestering properties in polyamine sulfonamides. Antimicrob Agents Chemother. 2009;53(1):57–62PubMedCrossRef
42.
go back to reference Litvak Y, et al. Dysbiotic Proteobacteria expansion: a microbial signature of epithelial dysfunction. Curr Opin Microbiol. 2017;39:1–6PubMedCrossRef Litvak Y, et al. Dysbiotic Proteobacteria expansion: a microbial signature of epithelial dysfunction. Curr Opin Microbiol. 2017;39:1–6PubMedCrossRef
43.
go back to reference Quigley EM, Stanton C, Murphy EF. The gut microbiota and the liver Pathophysiological and clinical implications. J Hepatol. 2013;58(5):1020–1027PubMedCrossRef Quigley EM, Stanton C, Murphy EF. The gut microbiota and the liver Pathophysiological and clinical implications. J Hepatol. 2013;58(5):1020–1027PubMedCrossRef
44.
go back to reference Bajaj JS, et al. Specific gut and salivary microbiota patterns are linked with different cognitive testing strategies in minimal hepatic encephalopathy. Am J Gastroenterol. 2019;114(7):1080–1090PubMedPubMedCentralCrossRef Bajaj JS, et al. Specific gut and salivary microbiota patterns are linked with different cognitive testing strategies in minimal hepatic encephalopathy. Am J Gastroenterol. 2019;114(7):1080–1090PubMedPubMedCentralCrossRef
45.
go back to reference Bajaj JS, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 2014;60(5):940–947PubMedCrossRef Bajaj JS, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 2014;60(5):940–947PubMedCrossRef
47.
go back to reference Bajaj JS, et al. Cognition and hospitalizations are linked with salivary and faecal microbiota in cirrhosis cohorts from the USA and Mexico. Liver Int. 2020;40(6):1395–1407PubMedCrossRef Bajaj JS, et al. Cognition and hospitalizations are linked with salivary and faecal microbiota in cirrhosis cohorts from the USA and Mexico. Liver Int. 2020;40(6):1395–1407PubMedCrossRef
48.
go back to reference Hollister EB, Gao C, Versalovic J. Compositional and functional features of the gastrointestinal microbiome and their effects on human health. Gastroenterology. 2014;146(6):1449–1458PubMedCrossRef Hollister EB, Gao C, Versalovic J. Compositional and functional features of the gastrointestinal microbiome and their effects on human health. Gastroenterology. 2014;146(6):1449–1458PubMedCrossRef
49.
go back to reference Bajaj JS, et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol. 2012;303(6):G675–G685PubMedPubMedCentralCrossRef Bajaj JS, et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol. 2012;303(6):G675–G685PubMedPubMedCentralCrossRef
50.
go back to reference Eppinga H, et al. Similar depletion of protective Faecalibacterium prausnitzii in psoriasis and inflammatory bowel disease, but not in Hidradenitis Suppurativa. J Crohns Colitis. 2016;10(9):1067–1075PubMedCrossRef Eppinga H, et al. Similar depletion of protective Faecalibacterium prausnitzii in psoriasis and inflammatory bowel disease, but not in Hidradenitis Suppurativa. J Crohns Colitis. 2016;10(9):1067–1075PubMedCrossRef
51.
go back to reference Chen Y, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology. 2011;54(2):562–572PubMedCrossRef Chen Y, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology. 2011;54(2):562–572PubMedCrossRef
52.
go back to reference Ahn SB, et al. Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease. Sci Rep. 2019;9(1):5688PubMedPubMedCentralCrossRef Ahn SB, et al. Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease. Sci Rep. 2019;9(1):5688PubMedPubMedCentralCrossRef
53.
go back to reference Seo B, et al. Roseburia spp. abundance associates with alcohol consumption in humans and its administration ameliorates alcoholic fatty liver in mice. Cell Host Microbe. 2020;27(1):25-40.e6PubMedCrossRef Seo B, et al. Roseburia spp. abundance associates with alcohol consumption in humans and its administration ameliorates alcoholic fatty liver in mice. Cell Host Microbe. 2020;27(1):25-40.e6PubMedCrossRef
55.
56.
go back to reference Meehan CJ, Beiko RG. Lateral gene transfer of an ABC transporter complex between major constituents of the human gut microbiome. BMC Microbiol. 2012;12(1):248PubMedPubMedCentralCrossRef Meehan CJ, Beiko RG. Lateral gene transfer of an ABC transporter complex between major constituents of the human gut microbiome. BMC Microbiol. 2012;12(1):248PubMedPubMedCentralCrossRef
57.
go back to reference Liu Y, et al. Gut Microbiome and metabolome response of Pu-erh Tea on metabolism disorder induced by chronic alcohol consumption. J Agric Food Chem. 2020;68(24):6615–6627PubMedCrossRef Liu Y, et al. Gut Microbiome and metabolome response of Pu-erh Tea on metabolism disorder induced by chronic alcohol consumption. J Agric Food Chem. 2020;68(24):6615–6627PubMedCrossRef
58.
go back to reference Enooku K, et al. Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma. Sci Rep. 2019;9(1):10663PubMedPubMedCentralCrossRef Enooku K, et al. Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma. Sci Rep. 2019;9(1):10663PubMedPubMedCentralCrossRef
59.
go back to reference Jeyapal S, et al. Substitution of linoleic acid with alpha-linolenic acid or long chain n-3 polyunsaturated fatty acid prevents Western diet induced nonalcoholic steatohepatitis. Sci Rep. 2018;8(1):10953PubMedPubMedCentralCrossRef Jeyapal S, et al. Substitution of linoleic acid with alpha-linolenic acid or long chain n-3 polyunsaturated fatty acid prevents Western diet induced nonalcoholic steatohepatitis. Sci Rep. 2018;8(1):10953PubMedPubMedCentralCrossRef
60.
Metadata
Title
Characteristics of microbiome-derived metabolomics according to the progression of alcoholic liver disease
Authors
Raja Ganesan
Haripriya Gupta
Jin-Ju Jeong
Satya Priya Sharma
Sung-Min Won
Ki-Kwang Oh
Sang Jun Yoon
Sang Hak Han
Young Joo Yang
Gwang Ho Baik
Chang Seok Bang
Dong Joon Kim
Ki Tae Suk
Publication date
31-03-2023
Publisher
Springer India
Published in
Hepatology International / Issue 2/2024
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-023-10518-9

Other articles of this Issue 2/2024

Hepatology International 2/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.